Patient's Whole Process Follow-up Management(HOPE-1)
A Multicenter, Randomized, Open, Parallel Grouping, Investigator-initiated Study Evaluating the Long-term Benefit of Patients With Locally Advanced/Metastatic Non-small Cell Lung Cancer Followed up Using a Patient-wide Management Platform
Qianfoshan Hospital
1,268 participants
May 22, 2022
OBSERVATIONAL
Conditions
Summary
Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.
Eligibility
Inclusion Criteria7
- Fully understand the research and voluntarily sign the informed consent form (ICF)
- Male or female subjects who are over 18 years old (inclusive) at the time of signing the informed consent form.
- The subject is diagnosed pathologically or cytologically with non-small cell lung cancer(NSCLC).
- According to the 8th edition of the American Joint Committee on Cancer \[AJCC\], it is classified as stage IIB, stage III, stage IV NSCLC.
- Not suitable for radical treatment or refuse surgery.
- The life expectancy is not less than 3 months.
- Be able to use a smartphone.
Exclusion Criteria5
- Patients with mental illness.
- Presence of any other malignant tumor.
- Patients who are expected to undergo radical surgery.
- Currently participating in clinical trials.
- Subjects who judged by the investigator to be unsuitable to participate in the trial.
Interventions
Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05339568